French Study Says Pfizer-Biontech Vaccine Less Effective against Indian Variant
A study by France’s Pasteur Institute found people who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the B. 1.617 variant.
The Pfizer vaccine is slightly less effective but appears to still protect against the more transmissible Covid-19 variant first identified in India, according to a study by France’s Pasteur Institute.
“Despite slightly diminished efficacy, the Pfizer vaccine probably protects” against the Indian variant, according to laboratory test results, said Olivier Schwartz, the institute’s director and co-author of the study that was published on the BioRxiv website ahead of peer review.
The study sampled 28 health care workers in the city of Orleans. Sixteen of them had received two doses of the Pfizer vaccine, while 12 had received one dose of the AstraZeneca vaccine.
People who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the Indian variant, B. 1.617, according to the study, but were still protected.
Since first emerging in late 2019 in China, the SARS-CoV-2 virus that causes Covid-19 has developed several variants, usually named for the places where it first appeared including the so-called South Africa and UK strains.
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
- » Bulgaria: Here is where you can get Vaccinated during the Weekend
- » Europe in Fear of the New Covid “Botswana Mutation”: What do we know about it
- » WHO Warns: Sense of Security of those Vaccinated against COVID-19 is Deceptive
- » The Anti-Covid “Merck” Pill turns out as not very Effective
- » First European Case of the New COVID Variant was Discovered in Belgium
- » Ministry of Health: We are Leaving the Dark Red Zone, the New Strain has Not Arrived